Abeona Therapeutics (ABEO) stock
Follow ABEO's trial news. Members get an alert when Abeona Therapeutics files news, and see its trials, share raises, and its CEO's filings.
What's next for ABEO, and how long its cash lasts
From Abeona Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 7 quarters
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why ABEO scores -6
PoorTrending up, 0 of 14 checks firingWhat the Quality Score means
- −3Long-term trend below a falling 200-day, down over one year, down over two years
- −1Profit Lost $63M over the last four quarters, after a profit of $57M the four before, from the SEC filings
- Cash flow subtracts
- Insider trades subtracts
What's next
Expected to report Wed Nov 11, before the open
After its last 4 reports it closed +0.1% on average, higher 2 of 4 times.
What would turn ABEO's score around: 6 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
Nothing is firing on ABEO right now
One per group is shown here.
How ABEO ranks in Biotech
ABEO is #258 of 276 by Quality Score. The top three are shown with their scores, and the rest by name.
ABCL10/1420
EXEL9/1419
RGEN7/1419
ONCOpen for its score
PBYIOpen for its score
ABEO0/14-6
When does ABEO report, and what happens after?
Expected to report Wed Nov 11, before the open (in 42 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 13, 2026Before open | Before open | -18.4% | -14.9% | -17.8% |
| May 13, 2026Before open | Before open | +2.3% | +0.5% | -9.9% |
| Mar 17, 2026Before open | Before open | -3.4% | -3.8% | -10.7% |
| Nov 12, 2025Before open | Before open | +8.6% | +18.5% | +7.4% |
Who is trading ABEO
Insiders
7 insiders sold $1.7M across 18 filings in the last 6 months. No open-market buys on record. The newest:
About Abeona Therapeutics
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of ABEO's score, with the points and the reason
- All 14 checks on ABEO and on all 2,952 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ABEO
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.